A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple-Negative Breast Cancer
Interventions: DRUG: Anti-PD-1 monoclonal antibody|DRUG: VEGFR2 Tyrosine Kinase Inhibitor
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University